142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
415 432 9270
https://www.89bio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 70
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Rohan Palekar | CEO & Director | 1.06M | N/D | 1966 |
Mr. Quoc Le-Nguyen | Chief Technical Officer | 702.87k | N/D | 1968 |
Dr. Harry Mansbach M.D. | Chief Medical Officer | 732.87k | N/D | 1965 |
Mr. Ryan Stephen Martins | Chief Financial Officer | N/D | N/D | 1979 |
Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | N/D | N/D | 1966 |
Ms. Annie J. Chang M.B.A. | VP of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Ms. Amanda Kurihara | Vice President of People & Culture | N/D | N/D | N/D |
Ms. Melissa Abel | Senior Vice President of Commercial Strategy | N/D | N/D | N/D |
Mr. Paul Shin | Senior Vice President of R&D Operations | N/D | N/D | N/D |
Mr. Michael Baldwin | VP & Head of Quality | N/D | N/D | N/D |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
La calificación ISS Governance QuickScore de 89bio, Inc. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 8; Compensación: 8.